东北制药DCTY0801注射液临床试验获批

Core Viewpoint - Northeast Pharmaceutical's subsidiary, Beijing Dingcheng Peptide Source Biotechnology Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of DCTY0801 injection, marking a significant milestone in the product's development [1] Company Summary - DCTY0801 injection targets the EGFRvIII mutation antigen and is a CAR-T cell product aimed at treating recurrent or progressive high-grade gliomas [1] - The approval of the clinical trial for DCTY0801 injection is expected to accelerate the development progress of the company's pipeline products and enhance its core competitiveness in the field of cancer treatment [1]